Director, Value Outcomes Liaison

Department: Medical Affairs

Date Posted: 11/6/2025

Location: Field Based role (opportunities on East and West coasts)

About Summit

Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people.

Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence.

Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including:

Non-small Cell Lung Cancer (NSCLC)

HARMONi:
Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI.

HARMONi-3:
Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.

HARMONi-7:
Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC.

HARMONi-GI3:
Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.

Summit Therapeutics is seeking a Director, Value Outcomes Liaison, to join our mission of developing Ivonescimab, a novel and unique immunotherapy with the potential to help patients suffering from life‑threatening cancers.

The Director, Value Outcomes Liaison is a critical member of an expanding team, responsible for interfacing with US population‑based decision makers (PBDMs) including payers, health systems, clinical pathway organizations, P&T committees, and policy makers. You will educate key stakeholders on clinical, economic, and humanistic impact of ivonescimab to help inform formulary access, pathway/guideline decisions, and improve lives of cancer patients. Providing objective and scientifically sound medical information on ivonescimab and the relevant disease states through use of economic models, outcomes tools, educational programs, and collaborations to enhance key stakeholder recognition of Summit Therapeutics.

You will compliantly partner with the commercial market access field team to facilitate access to ivonescimab through proactive engagement with organized customers, ensuring the delivery of accurate, non‑promotional medical information.

• Independently cultivate and manage relationships with PBDMs, acting as primary point of contact and collaborating closely with other field roles to ensure an aligned approach to stakeholder engagement
• Collaborate with internal HEOR team and market access team, to execute on scientific engagement strategy for appropriate stakeholders (e.g., Payers, PBMs, GPOs, IDNs and Oncology Pathways) within a territory or customer base
• Serve as a conduit and resource for providing clinical and healthcare economic information (HCEI) to payers and formulary decision‑makers
• Maintaining required knowledge of ivonescimab, to proactively and reactively communicate clinical and economic information related to ivonescimab to advance formulary decision‑making and improve patient outcomes
• Capture and communicate internally key stakeholder insights and evidence gaps/needs including potential opportunities for collaboration
• U…